Could Tau PET Replace Amyloid Biomarkers for AD?
A large, cross-sectional study finds that RO-948 PET discriminates AD dementia from other disorders more accurately than do CSF biomarkers or MRI
A large, cross-sectional study finds that RO-948 PET discriminates AD dementia from other disorders more accurately than do CSF biomarkers or MRI
Genome-wide association studies have uncovered risk variants for neurologic diseases, but in which cells are these disease genes doing their dirty work?
James Watson is investigating the socio-economic and geographic variation in care pathways and the resulting health and economic outcomes for older populations.
Many people with Lewy body diseases (LBDs) ultimately develop dementia, and many have Aβ plaques & tau. Do they have two diseases at the same time?
At the virtual AAT-AD/PD Focus meeting, clinicians and funders involved in the DIAN-TU Trial discuss results from the first DIAN-TU treatment trial
Clarissa Giebel updates on her recent trip to Maastricht for her Alzheimer’s Society funded project, and discusses differences in study recruitment.
Details from the first Tau2020 Conference held in Washington, D.C. last month, shared from the Alz Forum.
It may seem counter intuitive, but could BACE2 protect against amyloidosis, rather than contribute to it? Find out in the post shared from the Alz Forum website
The notorious amyloid precursor protein, central to Alzheimer’s disease pathogenesis, sports a new look on Alzforum’s Mutations database.
Researchers led by Marco Colonna and Maxim Artyomov at Washington University School of Medicine in St. Louis report distinct transcriptional changes in several cell types in human AD brains compared with those of 5XFAD mice.
Paper report that age-related cracks in the blood-brain barrier allow an influx of serum protein albumin into the brain, where they activate TGFβ receptors, overexcite neuronal networks, and impairing cognition.
For brain cells, what do aging, living in white matter, and hanging out with tumors have in common?